• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis

    Thumbnail
    View/Open
    KalincikPUB861.PDF (374.5Kb)
    Author(s)
    Kalincik, T
    Spelman, T
    Trojano, M
    Duquette, P
    Izquierdo, G
    Grammond, P
    Lugaresi, A
    Hupperts, R
    Cristiano, E
    Van Pesch, V
    Grand'Maison, F
    La Spitaleri, D
    Rio, ME
    Flechter, S
    Oreja-Guevara, C
    Giuliani, G
    Savino, A
    Amato, MP
    Petersen, T
    Fernandez-Bolanos, R
    Bergamaschi, R
    Iuliano, G
    Boz, C
    Lechner-Scott, J
    Deri, N
    Gray, O
    Verheul, F
    Fiol, M
    Barnett, M
    Van Munster, E
    Santiago, V
    Moore, F
    Slee, M
    Saladino, ML
    Alroughani, R
    Shaw, C
    Kasa, K
    Petkovska-Boskova, T
    Den Braber-Moerland, L
    Chapman, J
    Skromne, E
    Herbert, J
    Poehlau, D
    Needham, M
    Bacile, EAB
    Arruda, WO
    Paine, M
    Singhal, B
    Vucic, S
    Cabrera-Gomez, JA
    Butzkueven, H
    Griffith University Author(s)
    Slee, Mark
    Butzkueven, Helmut
    Year published
    2013
    Metadata
    Show full item record
    Abstract
    Objectives: To compare treatment persistence between two dosages of interferon b-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Methods: Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon b-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon b-1a in either dosage (22 mg or 44 mg) as their first disease modifying agent, matched on ...
    View more >
    Objectives: To compare treatment persistence between two dosages of interferon b-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Methods: Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon b-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon b-1a in either dosage (22 mg or 44 mg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Results: Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as ‘‘lack of efficacy’’ (3.3% vs. 1.7%), ‘‘scheduled stop’’ (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 mg vs. 44 mg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Conclusions: Treatment discontinuations were more common in interferon b-1a 22 mg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from ‘‘real-world’’ database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.
    View less >
    Journal Title
    PloS One
    Volume
    8
    Issue
    5
    DOI
    https://doi.org/10.1371/journal.pone.0063480
    Copyright Statement
    © 2013 Kalincik et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    Subject
    Medical and Health Sciences not elsewhere classified
    Publication URI
    http://hdl.handle.net/10072/59953
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander